BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 29266965)

  • 1. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β
    Stolz D; Hirsch HH; Schilter D; Louis R; Rakic J; Boeck L; Papakonstantinou E; Schindler C; Grize L; Tamm M
    Am J Respir Crit Care Med; 2018 May; 197(9):1136-1146. PubMed ID: 29266965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overuse of long-acting β
    Brunton SA; Hogarth DK
    Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
    Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
    Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
    Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
    Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
    Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
    Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.
    Wise RA; Scirica BM; Bhatt DL; Daoud SZ; Chuecos F; Garcia Gil E; Chapman KR
    Adv Ther; 2021 Oct; 38(10):5381-5397. PubMed ID: 34528220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
    Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
    NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status.
    Reilev M; Kristensen KB; Søndergaard J; Henriksen DP; Thompson W; Pottegård A
    Eur J Clin Pharmacol; 2019 Jul; 75(7):1025-1032. PubMed ID: 30903196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data.
    Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.
    Yang SN; Ko HK; Hsiao YH; Su KC; Chang YL; Huang HY; Perng DW; Chung MI
    J Chin Med Assoc; 2019 Jun; 82(6):488-494. PubMed ID: 31180947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Noninferiority Trial Comparing ICS + LABA with ICS + LABA + LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study.
    Park SY; Kim S; Kim JH; Kim SH; Lee T; Yoon SY; Kim MH; Moon JY; Yang MS; Jung JW; Kim JH; Choi JH; Park CS; Kim S; Lee J; Kwon JW; Hur GY; Kim SH; Kim HK; Shin YS; Kim SH; Nam YH; Jang AS; Park SY; Kim TB;
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1304-1311.e2. PubMed ID: 33184024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S; Dell'Aniello S; Ernst P
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
    Oba Y; Chandran AV; Devasahayam JV
    COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
    Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
    COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.